N
NEUROONE MEDICAL TECHNOLOGIES Corp
NMTCCIK 0001500198NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Sep 30
Period
FY 2025
Revenue
$9.10M
Net Income
$-3.61M
Total Assets
$10.79M
Equity
$7.07M
Shares Out
50.43M
Op. Cash Flow
$-2.84M
Business
NeuroOne Medical Technologies Corp is a medical technology company developing diagnostic, ablation and stimulation technologies for brain disorders, pain management and device-enabled drug delivery. It offers thin-film cortical and depth electrodes (Evo Cortical, Evo sEEG), OneRF radiofrequency ablation systems for brain and trigeminal nerve procedures, and is developing spinal cord stimulation, basivertebral nerve ablation and drug‑delivery electrodes. Its business is organized around commercialized neurosurgical devices, products in development and collaborative research and distribution partnerships. The company sells primarily in the United States and via distributors to hospitals, epilepsy centers and clinicians internationally.
Summary from filing dated 2025-12-17
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Product revenue | 9 | 3 | 2 | 171,169 | 178,146 | |
| Cost of product revenue | 4 | 2 | 1 | 241,963 | 275,895 | |
| Product gross profit | 5 | 1 | 456,517 | −70,794 | −97,749 | |
| Collaborations revenue | 3 | — | — | — | — | |
| Selling, general and administrative | 7 | 8 | 7 | 7 | 6 | |
| Research and development | 5 | 5 | 7 | 5 | 4 | |
| Total operating expenses | 12 | 13 | 14 | 12 | 10 | |
| Loss from operations | −4 | −12 | −12 | −10 | −10 | |
| Fair value change in warrant liability | 784,670 | −327,092 | — | — | — | |
| Financing costs | −334,063 | −228,988 | — | — | — | |
| Other income, net | 170,492 | 125,179 | — | — | — | |
| Loss before income taxes | −4 | −12 | −12 | −10 | — | |
| Provision for income taxes | — | — | — | — | 271,122 | |
| Net loss | −4 | −12 | −12 | −10 | −10 | |
| Basic (in Dollars per share) | −0.09 | −0.46 | −0.65 | −0.63 | −0.93 | |
| Diluted (in Dollars per share) | −0.09 | −0.46 | −0.65 | −0.63 | −0.93 | |
| Basic (in Shares) | 40 | 27 | 18 | 16 | 11 | |
| Diluted (in Shares) | 40 | 27 | 18 | 16 | 11 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 1 | 5 | 8 | 7 | |
| Accounts receivable | 1 | 176,636 | — | 33,237 | 48,336 | |
| Inventory | 2 | 3 | 2 | 704,538 | 98,287 | |
| Deferred offering costs | 22,920 | 142,633 | — | — | — | |
| Prepaid expenses | 141,372 | 216,461 | 263,746 | 296,649 | 244,043 | |
| Total current assets | 10 | 5 | 7 | 12 | 7 | |
| Intangible assets, net | 44,946 | 67,262 | 89,577 | 111,892 | 134,207 | |
| Right-of-use asset | 255,195 | 254,910 | 169,059 | 181,355 | 288,948 | |
| Property and equipment, net | 259,222 | 416,843 | 525,753 | 353,599 | 223,329 | |
| Total assets | 11 | 5 | 8 | 13 | 8 | |
| Accounts payable | 1 | 1 | 685,104 | 927,662 | 528,829 | |
| Accrued expenses and other liabilities | 1 | 1 | — | — | — | |
| Total current liabilities | 2 | 2 | 2 | 3 | 1 | |
| Warrant liability | 1 | 2 | — | — | — | |
| Operating lease liability, long term | 143,148 | 194,392 | 55,284 | 119,556 | 202,895 | |
| Total liabilities | 4 | 5 | 2 | 3 | 1 | |
| Commitments and contingencies (Note 4) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding. | — | — | — | — | — | |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 50,006,464 and 30,816,499 shares issued and outstanding as of September 30, 2025 and 2024, respectively. | 50,006 | 30,816 | 23,929 | 16,217 | 12,010 | |
| Additional paidin capital | 86 | 76 | 69 | 60 | 47 | |
| Accumulated deficit | −79 | −75 | −63 | −51 | −41 | |
| Total stockholders equity | 7 | 822,013 | 6 | 10 | 7 | |
| Total liabilities and stockholders equity | 11 | 5 | 8 | 13 | 8 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Amortization and depreciation | 261,679 | 246,791 | 199,266 | — | — | |
| Amortization of deferred issuance costs | 192,647 | 101,329 | — | — | — | |
| Stock-based compensation | 1 | 1 | 1 | 947,212 | — | |
| Debt and equity facility costs reclassified to financing activities | 141,416 | 127,659 | — | — | — | |
| Non-cash lease expense | 111,613 | 113,534 | 109,832 | — | — | |
| Valuation adjustments for excess or obsolete inventory | 10,000 | — | — | — | — | |
| Accounts receivable | −1 | −176,636 | 33,237 | 15,099 | −48,336 | |
| Inventory | 398,348 | −908,467 | −1 | −606,251 | −98,287 | |
| Prepaid expenses | 75,089 | 47,285 | 32,903 | — | — | |
| Accounts payable | 239,983 | 66,993 | −247,189 | 515,438 | −350,313 | |
| Accrued expenses, operating lease and other liabilities | −54,442 | 16,214 | −1 | 1 | — | |
| Net cash used in operating activities | −3 | −11 | −13 | −8 | −9 | |
| Purchases of property and equipment | −81,742 | −120,197 | −384,117 | −275,226 | −67,079 | |
| Net cash used in investing activities | −81,742 | −120,197 | 3 | −3 | −67,079 | |
| Proceeds from issuance of common stock in connection with private placement | — | 836,777 | — | — | — | |
| Proceeds from issuance of warrants in connection with private placement | — | 2 | — | — | — | |
| Proceeds from issuance of common stock attributed to non-private placement equity offerings | 10 | 5 | — | — | — | |
| Issuance costs attributed to common stock and warrants issued in private placement | −185,903 | −1,320 | — | — | — | |
| Issuance costs related to non-private placement equity offerings | −1 | −236,597 | — | — | — | |
| Deferred issuance costs in connection with at-the-market offering program | — | −20,000 | −234,725 | — | — | |
| Deferred issuance costs in connection with debt facility | −297,942 | −75,000 | — | — | — | |
| Exercise of warrants | 69,750 | — | — | — | 275,000 | |
| Share repurchases for the payment of employee taxes | −124,617 | −81,403 | −119,419 | — | — | |
| Net cash provided by financing activities | 8 | 7 | 7 | 12 | 12 | |
| Net increase (decrease) in cash and cash equivalents | 5 | −4 | −3 | 1 | 3 | |
| Modification of right-of-use asset and associated lease liability | 111,898 | 199,385 | 97,536 | — | — | |
| Non-cash warrants issued in connection with debt facility | — | 53,124 | — | — | — | |
| Unpaid issuance costs in connection with private placement | — | 185,903 | — | — | — | |
| Unpaid deferred issuance costs | 22,920 | 95,837 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro